Ignyta announces release for clinical use of a proprietary NGS clinical trial assay
Ignyta announced the release for clinical use of its first clinical trial assay to support patient identification and enrollment into its STARTRK ("Studies of Tumor Alterations Responsive to Targeting Receptor Kinases") clinical development program for entrectinib. June 30, 2015